The theory is solid, but creating such a bespoke vaccine quickly enough to be of use is a different matter. “Not many years ...

Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Cells is under clinical development by ICamuno Biotherapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition ...

Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer Research (ICR), ...

Ingelheim, Germany Thursday, January 9, 2025, 15:00 Hrs [IST] ...

Every woman has a one in 87 chance of getting ovarian cancer in her lifetime, and one in 130 will die from it.

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

A noninvasive method involving brief, localized pulses of magnetic fields could improve chemotherapy effectiveness and reduce ...